Embracing the transformational potential of new molecular profiling and artificial-intelligence-based data processing technologies on clinical and scientific innovation, Weill Cornell Medicine has created a new research department, the Department of Systems and Computational Biomedicine. Dr.
A Conversation with Eleni Andreopoulou, M.D.
September 2, 2026
Q: What first drew you to medicine, and later to breast oncology?
Dr. Andreopoulou:
I was drawn to medicine from an early age by both intellectual curiosity and a desire to care for others. I grew up in a family that deeply valued education and service, and those values, combined with my love of biology, chemistry, and pharmacology, naturally led me toward medicine.
September 2026 EIPM Director's Memo
September 1, 2026
Dear Friends & Members of the Englander Institute,
Model Helps Scientists Build Better Protein-Degrading Therapies
August 31, 2026
A team of Weill Cornell Medicine investigators has developed a computer model that will help scientists more efficiently develop protein-destroying therapies, a newer type of treatment that is particularly promising for cancer. The studywas published July 13 in Nature Communications.
Radiopharmaceutical May Benefit Patients with Metastatic Prostate Cancer Sooner
August 7, 2026
Earlier use of a targeted radionuclide therapy delays metastatic prostate cancer progression when administered as part of a trio of drugs, according to a phase 3 clinical trial led by Weill Cornell Medicine, NewYork-Presbyterian, Memorial Sloan Kettering Cancer Center and investigators at several other institutions worldwide.
Mapping Human Bone Marrow Yields New Tool, Insights on Blood Cancer
July 21, 2026
Weill Cornell Medicine investigators have developed a new AI-based method to assess patients with a form of blood cancer called myelodysplastic neoplasms.
Tumor Organoid Tech Advances Toward a Sci-Fi Future
July 20, 2026
Significant advances have been made in the development of patient-derived tumor organoids for preclinical research, in two new studies led by Weill Cornell Medicine investigators. The advances represent progress in precision medicine and point to the more routine use of tumor organoids as models for evaluating and optimizing cancer treatments.
Cancer evolution study reveals biology of glioma progression
July 14, 2026
A type of brain cancer, called glioma, tends to progress toward greater malignancy due to an increasing tendency of the glioma cells to transform into immature, stem-cell-like states, according to a study led by investigators at Weill Cornell Medicine, the New York Genome Center, Harvard Medical School and Mass General Brigham.
The findings showcase the power of modern laboratory technology for illuminating cancer development, and could inform future treatments and prognostic measures for gliomas.
Discovery Could Lead to Drug Therapy for Hypopigmentation Conditions
July 14, 2026
An NSAID-related compound called ampyrone appears to safely boost production of the pigment melanin in human skin, according to a preclinical study led by Weill Cornell Medicine and National Eye Institute investigators. The discovery could lead to the development of an ampyrone-derived treatment for hypopigmentation disorders.